Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab in MAS in Still's Disease or SLE
NCT05001737Phase 3Completed
- Sponsor
- Sobi
- Start
- Dec 2021
- Primary completion
- Jun 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of emapalumab in macrophage activation syndrome (MAS), sponsored by Sobi. Primary endpoint: Complete Response at 8 weeks. Started Dec 2021; status: completed.
02
Drugs
emapalumab
03
Conditions
macrophage activation syndrome (MAS)
Beyond the preview
Go deeper on NCT05001737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001737.